Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines

This study has been completed.
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00698100
First received: June 12, 2008
Last updated: September 15, 2011
Last verified: September 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2011
  Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)